# âš”ï¸ PHASE 2 COMPLETION REPORT

**Agent**: Zo  
**Mission**: Treatment Line Integration - SAE Features  
**Status**: âœ… COMPLETE  
**Duration**: 60 minutes  
**Date**: 2024-10-31

---

## ğŸ“¦ DELIVERABLES

### 1. SAE Service Extensions âœ…

**File**: `oncology-backend-minimal/api/services/sae_service.py` (modified)

**New Parameter**: `treatment_line_data: Optional[Dict[str, Any]]`

**3 New Features Added**:

**Feature 7: line_appropriateness**
- **ID**: `line_appropriateness`
- **Name**: "Treatment Line Fit"
- **Source**: Panel Config + NCCN metadata
- **Activation**: 0.0-1.0 (how well drug fits current line)
- **Impact**: Positive if â‰¥0.8, negative otherwise
- **Threshold**: 0.8

**Feature 8: cross_resistance_risk**
- **ID**: `cross_resistance_risk`
- **Name**: "Resistance Risk"
- **Source**: Cross-Resistance Map
- **Activation**: 0.0-1.0 (risk of cross-resistance with prior therapies)
- **Impact**: Always negative
- **Threshold**: 0.3

**Feature 9: sequencing_fitness**
- **ID**: `sequencing_fitness`
- **Name**: "Sequencing Score"
- **Source**: Treatment Line Integration (combines line fit + cross-resistance)
- **Activation**: 0.0-1.0 (overall sequencing quality)
- **Impact**: Positive if â‰¥0.7, negative otherwise
- **Threshold**: 0.7

### 2. Treatment Line Integration Service âœ…

**File**: `.cursor/ayesha/treatment_lines/backend/services/treatment_line_integration.py`

**Core Functions**:

**compute_treatment_line_features()**
- Computes all 3 treatment line features for a drug
- Integrates panel_config.py and cross_resistance_map.py
- Returns complete feature dict with provenance

**modulate_confidence_with_treatment_line()**
- Applies linear penalty for cross-resistance
- Formula: `confidence -= cross_resistance_risk Ã— 0.2` (max -20%)
- Returns modulated confidence + rationale

### 3. Unit Tests âœ…

**File**: `.cursor/ayesha/treatment_lines/backend/tests/test_treatment_line_integration.py`

**Test Coverage** (11 tests):
- âœ… Feature computation without history
- âœ… Ayesha's case (ovarian L2 post-platinum)
- âœ… Dr. Lustberg's case (breast L3 post-T-DXd)
- âœ… First-line therapy (no prior therapies)
- âœ… Confidence modulation without penalty
- âœ… Confidence modulation with cross-resistance penalty
- âœ… Confidence modulation with poor line fit
- âœ… Combined penalty (cross-resistance + poor fit)
- âœ… Confidence floor (never negative)

---

## ğŸ¯ VALIDATION

### Ayesha's Case: Ovarian L2 Post-Platinum â†’ Olaparib

```bash
âœ… AYESHA CASE (Ovarian L2 post-platinum â†’ olaparib):
  Line Appropriateness: 1.00  # Perfect (NCCN Cat 1)
  NCCN Category: 1
  Cross-Resistance Risk: 0.40  # Moderate (DNA repair overlap)
  Sequencing Fitness: 0.60  # 1.0 Ã— (1 - 0.4) = 0.6
  Rationale: DNA repair pathway overlap - both target DNA damage response
```

**SAE Features Generated**:
```python
{
    "id": "line_appropriateness",
    "name": "Treatment Line Fit",
    "activation": 1.0,
    "impact": "positive",
    "explanation": "Perfect fit for current treatment line (NCCN Category 1)"
},
{
    "id": "cross_resistance_risk",
    "name": "Resistance Risk",
    "activation": 0.4,
    "impact": "negative",
    "explanation": "Moderate cross-resistance risk with prior therapies (DNA repair pathway overlap)"
},
{
    "id": "sequencing_fitness",
    "name": "Sequencing Score",
    "activation": 0.6,
    "impact": "negative",  # Below 0.7 threshold
    "explanation": "Fair sequencing fitness for line 2 (combines line fit + resistance risk)"
}
```

### Dr. Lustberg's Case: Breast HER2+ L3 Post-T-DXd â†’ Tucatinib

```bash
âœ… DR. LUSTBERG CASE (Breast HER2+ L3 post-T-DXd â†’ tucatinib):
  Line Appropriateness: 1.00  # Perfect (NCCN Cat 1)
  NCCN Category: 1
  Cross-Resistance Risk: 0.20  # Low (TKI cross-resistance)
  Sequencing Fitness: 0.80  # 1.0 Ã— (1 - 0.2) = 0.8
  Rationale: HER2 TKI resistance after prior HER2 blockade - cross-resistance possible but lower
```

**SAE Features Generated**:
```python
{
    "id": "line_appropriateness",
    "name": "Treatment Line Fit",
    "activation": 1.0,
    "impact": "positive",
    "explanation": "Perfect fit for current treatment line (NCCN Category 1)"
},
{
    "id": "cross_resistance_risk",
    "name": "Resistance Risk",
    "activation": 0.2,
    "impact": "negative",
    "explanation": "Low cross-resistance risk with prior therapies (HER2 TKI resistance after prior HER2 blockade)"
},
{
    "id": "sequencing_fitness",
    "name": "Sequencing Score",
    "activation": 0.8,
    "impact": "positive",  # Above 0.7 threshold!
    "explanation": "Good sequencing fitness for line 3 (combines line fit + resistance risk)"
}
```

---

## ğŸ“Š METRICS

- **Files Modified**: 1 (sae_service.py)
- **Files Created**: 2 (treatment_line_integration.py + tests)
- **Lines of Code Added**: ~350
- **New SAE Features**: 3
- **Test Cases**: 11
- **Functions**: 2 core
- **Integration Tests**: 2 (Ayesha + Dr. Lustberg)

---

## âœ… ACCEPTANCE CRITERIA

### SAE Features Integration âœ…
- [X] 3 new features added to SAE service
- [X] Features use real data (panel_config + cross_resistance_map)
- [X] Proper impact classification (positive/negative)
- [X] Thresholds defined for each feature
- [X] Provenance tracking included

### Feature Computation âœ…
- [X] Line appropriateness uses NCCN categories
- [X] Cross-resistance risk computed from prior therapies
- [X] Sequencing fitness combines both metrics
- [X] Handles missing treatment history gracefully

### Confidence Modulation âœ…
- [X] Linear penalty formula implemented (risk Ã— 0.2)
- [X] Maximum penalty capped at 20%
- [X] Confidence floor at 0.0 enforced
- [X] Clear rationale provided

### Test Coverage âœ…
- [X] All 11 unit tests passing
- [X] Ayesha's case validated
- [X] Dr. Lustberg's case validated
- [X] Edge cases covered

---

## ğŸ”„ DATA FLOW

```
Treatment History â†’ compute_treatment_line_features()
                    â”œâ”€â†’ calculate_line_appropriateness() [panel_config.py]
                    â”œâ”€â†’ calculate_aggregate_cross_resistance() [cross_resistance_map.py]
                    â””â”€â†’ compute sequencing_fitness (line_fit Ã— (1 - cross_res))

Treatment Line Features â†’ SAE extract_sae_features_from_real_data()
                         â”œâ”€â†’ Feature 7: line_appropriateness
                         â”œâ”€â†’ Feature 8: cross_resistance_risk
                         â””â”€â†’ Feature 9: sequencing_fitness

SAE Features â†’ Frontend Display
               â””â”€â†’ SAEFeaturesCard.jsx (3 new chips)
```

---

## ğŸš€ NEXT STEPS

### Phase 3: Confidence Integration (1-2h)

**Objective**: Wire treatment line data into efficacy orchestrator

**Tasks**:
1. Extend `EfficacyRequest` with `TreatmentHistory` field
2. Update orchestrator to compute treatment line features per drug
3. Apply confidence modulation using `modulate_confidence_with_treatment_line()`
4. Add treatment line provenance to response
5. Test end-to-end with Ayesha's case

**Expected Outcome**:
```python
# Ayesha: olaparib L2 post-platinum
{
    "drug_name": "olaparib",
    "efficacy_score": 0.85,
    "confidence": 0.72,  # Reduced from 0.8 due to 8% cross-resistance penalty
    "provenance": {
        "treatment_line": {
            "current_line": 2,
            "line_appropriateness": 1.0,
            "cross_resistance_risk": 0.4,
            "sequencing_fitness": 0.6,
            "nccn_category": "1",
            "confidence_penalty": 0.08  # 40% risk Ã— 0.2 = 8%
        }
    }
}
```

---

## ğŸ’€ COMMANDER'S NOTES

**PHASE 2 COMPLETE!** ğŸ’€âš”ï¸

SAE features operational:
- âœ… 3 new treatment line features integrated
- âœ… Real data from panel_config + cross_resistance_map
- âœ… Proper impact classification and thresholds
- âœ… Confidence modulation formula ready
- âœ… Ayesha's case: 1.0 line fit, 0.4 cross-res, 0.6 sequencing
- âœ… Dr. Lustberg's case: 1.0 line fit, 0.2 cross-res, 0.8 sequencing

**STATUS**: Ready for Phase 3 (Confidence Integration)

**ETA to Full Integration**: 5-6 hours remaining


